STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #602 by analyst upside · 2026-06-27
DBVT
DBV Technologies S.A.
Healthcare · Market Cap $948M · P/E 0x
ANALYST PRICE TARGET
+148.8%
implied upside to consensus target
Current Price $16.01
Consensus Target $39.83
Bull Target $53.99
Bear Target $5.81
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
4
Hold
0
Sell
1
52-Week Low $8.51
52-Week High $26.18
YTD Return -16.0%
FUNDAMENTALS
Market Cap $948M
P/E Ratio (TTM) N/A
Forward P/E -33.3x
EPS (TTM) $-4.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $6M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.51
52-Week High $26.18
Current Price $16.01
Bear Target $5.81
Bull Target $53.99
● Now $16.01 ● Target $39.83
TRADING DATA
Avg Volume 257K
YTD Return -16.0%
Analyst Count 6
Consensus Buy
Upside to Target +148.8%
Last Updated 2026-06-27

ANALYST SUMMARY

DBV Technologies S.A. (DBVT) is currently trading at $16.01 with a Wall Street consensus price target of $39.83, implying potential upside of 148.8% over the next 12 months. 6 analysts currently cover DBVT, with a consensus rating of Buy — 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $53.99, while the most cautious has a target of $5.81.

DBVT operates in the Healthcare sector with a market capitalisation of $948M. The stock is down 16.0% year-to-date and is currently trading near the lower end of its 52-week range of $8.51 – $26.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DBVT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim reit
Buy → Buy 2026-05-04 62% win rate (8 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-01 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-03-27 Building track record
Guggenheim reit
Buy → Buy 2026-03-27 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-17 31% win rate (48 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2025-12-17 40% win rate (10 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2025-12-17 Building track record
Guggenheim — Reiterated
Buy → Buy 2025-12-17 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →